Clinical Trial Update: A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the immunogenicity, safety and tolerability of the quadrivalent HPV vaccine V501 in Chinese girls aged 9-19 and young women aged 20-26.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma in Situ
• Cervical Cancer
• Cervical Intraepithelial Neoplasia

Drugs mentioned

• Gardasil (V501) (HPV vaccine quadrivalent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ | Phase 3 | Status: COMPLETED | Results posted: 2020-05-04